Business · 07/07/2004Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for DAPTACEL Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of DAPTACEL, a human biological product, in accordance with federal regulations and following a submission to the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →